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Abstract
Background: Neuroendocrine tumours (NET) are tumours arising from neuroendocrine cells of
neural crest origin. They are characterised by the presence of neurosecretory granules which react
positively to silver stains and to specific markers including neuron specific enolase, synaptophysin
and chromogranin. Metastasis to the skin occurs infrequently but primary soft tissue NET is
excessively rare.
Case presentation: We report our experience with 3 such cases. In the first case, the NET
originated in muscle and was treated with wide surgical excision and adjuvant radiotherapy. The
second case presented as a subcutaneous mass in the foot and the tumour was positive on 123I
mIBG scan. She has had prolonged recurrence-free survival following primary hypo-fractionated
radiotherapy. In the third case, a cutaneous nodule proved to be a NET and at surgery, lymph node
disease was present. He has remained disease-free after surgical excision without the need for
external beam radiotherapy.
Conclusion:  These tumours appear to have a good prognosis. Complete excision offers
potentially curative treatment. Adjuvant radiotherapy may be helpful when the tumour margin is
narrow. For patients with unresectable disease or where surgery would not be appropriate,
radiotherapy appears to be an effective therapeutic option.
Background
Neuroendocrine tumours (NET) most commonly origi-
nate in the appendix, small intestine, rectum and bron-
chus [1,2]. The majority are of low-grade malignant
potential with an indolent course and can be termed "car-
cinoids". The release of 5-HT and other vasoactive sub-
stances into the systemic circulation gives rise to the
"carcinoid syndrome", consisting of flushing, wheezing,
diarrhoea and eventually right-sided valvular heart dis-
ease [3]. This syndrome is usually associated with bulky
liver metastases. Metastasis to skin has been reported but
typically occurs in association with metastases elsewhere
[4,5]. NET arising de novo in the skin are very rare and
there are no reports of these tumours originating in soft
tissues. We describe our experience of three cases.
Case presentation
Case 1
A 43 year old man presented with a four month history of
a slowly growing hard mass in his right upper thigh. He
had no systemic symptoms such as flushing, diarrhoea or
wheeze. A 3 × 3 cm mass was excised and found to have
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arisen in the right sartorius muscle extending into the rec-
tus femoris and vastus medialis. Histopathology revealed
skeletal muscle and subcutaneous tissues infiltrated by
polygonal cells containing neurosecretory granules (Fig-
ures 1a and 1b). Immunohistochemistry showed strong
and diffuse positivity for synaptophysin, chromogranin
(Figure 1c), cytokeratin (Figure 1d) Bcl-2 protein and neu-
ron-specific enolase (NSE) but negativity for S100,
desmin and epithelial membrane antigen (EMA). Electron
microscopy showed polygonal cells with deeply indented
nuclei and neurosecretory granules in the cytoplasm.
These appearances were consistent with a neuroendocrine
carcinoma. 24 hour urine 5HIAA concentration was ele-
vated at 92 mmol (normal: 9–31 nmol/24 h).
No tumour was demonstrated elsewhere: mIBG and octre-
otide scans were negative as were CT scans of thorax,
abdomen and pelvis.
Following excision he was treated with adjuvant radical
dose external beam radiotherapy to the thigh in view of
the depth of invasion of the tumour and its poor histolog-
ical features. Following treatment his 5HIAA concentra-
tions normalised and he remains free of relapse, five years
later.
Case 2
A 79 year frail old lady presented with a lump on the sole
of the right foot which had gradually increased in size over
the previous nine months. The right leg had gradually
become more swollen and painful. She had not experi-
enced flushing attacks or diarrhoea. On examination there
was a hard subcutaneous mass on the plantar surface of
the right foot involving the metatarsal heads with associ-
ated erythema and thinning of the skin. The entire right
leg was swollen with lymphoedema.
A magnetic resonance (MR) scan was performed of the
right foot (Figure 2). This revealed a 7 × 5 cm mass involv-
ing skin, flexor compartment of the right sole and flexor
tendons. Core biopsy was performed for tissue diagnosis.
The appearance was of a necrotic tumour with pleomor-
phic epithelioid cells. Immunohistochemical staining
showed that the cells expressed neuroendocrine markers
(synaptophysin, chromogranin, NSE) and cytokeratin
marker (CAM 5.2) but were negative for S100, HMB45,
CD99 and CD117. The appearances were consistent with
a neuroendocrine tumour.
A  123I mIBG (meta-iodobenzylguanidine) scan revealed
increased uptake into the tumour consistent with its neu-
roendocrine origin (Figure 3).
MRI of the right foot in Case 2 Figure 2
MRI of the right foot in Case 2. A 7 × 5 cm mass is present 
involving the skin and flexor tendons.
(a) Rows of cells divided by fine fibrovascular stroma into a  packet arrangement Figure 1
(a) Rows of cells divided by fine fibrovascular stroma into a 
packet arrangement. This arrangement is typical of an endo-
crine tumour (H&E × 10). (b) Fine stroma with relatively uni-
form-looking cells and nuclear irregularity. The nuclear 
irregularity suggests that the tumour is not benign (H&E × 
40). (c) High power showing granular cytoplasmic staining 
with anti-chromogranin antibody. (d) High power showing 
diffuse cytoplasmic staining with anti-cytokeratin antibodyWorld Journal of Surgical Oncology 2007, 5:77 http://www.wjso.com/content/5/1/77
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CT scans of the chest, abdomen and pelvis showed meta-
static lymph node enlargement in the right groin and pel-
vic side wall but no pathology in the liver or lungs.
Radical surgery was not possible because of the extent of
tumour and the patient's general condition. Uptake of
mIBG was deemed inadequate to contemplate curative
treatment with a therapeutic dose of 131I mIBG. Instead,
the patient was treated with external beam radiotherapy to
the right foot (using 20 MeV electron beam) and to the
right side of the pelvis (with parallel pairs of photons).
The tumour dose was 30 Gy in 5 fractions with treatment
given over 4 weeks (6 Gy once weekly).
MR scanning 10 months later revealed significant reduc-
tion in tumour size (3 × 1.5 cm) and no residual pelvic
side-wall or inguinal disease. When last reviewed she was
well with no cancer-related symptoms. The nodule on the
sole of the right foot had not changed over 55 months fol-
low-up and the lymphoedema had completely resolved.
Case 3
A 61 year old retired civil servant was noted to have a
swelling over the left iliac crest. Fourteen months previ-
ously he had undergone wide local excision and local
radiotherapy for a high grade spindle cell sarcoma affect-
ing the lower left leg. The site was well-healed with no evi-
dence of recurrence. At follow-up, a 2 cm cutaneous
nodule was noted over the left iliac crest; it was fleshy and
smooth in consistency, being darker than surrounding
skin. There were no palpable lymph nodes. He had no sys-
temic symptoms such as flushing or diarrhoea.
Fine needle aspiration cytology (FNAC) of the nodule sug-
gested malignancy. A skin ellipse was resected and
included tumour nodules in the deep dermis. Immuno-
histochemistry showed strong and diffuse positive stain-
ing for neuroendocrine markers (NSE, chromogranin,
synaptophysin) and CAM 5.2 but was negative for EMA,
S100 and HMB45.
Histology was compared with the previous sarcoma but
was totally different. Appearances were interpreted as con-
sistent with a neuroendocrine tumour. 24 h urinary
5HIAA concentration was normal. CT scans of thorax,
abdomen and pelvis revealed a 1.5 cm inguinal lymph
node. FNAC of the node revealed malignant cells. An
octreotide scan showed no sign of visceral metastasis or
occult primary tumour. A left inguinal dissection was per-
formed; eleven nodes were removed with one showing
neuroendocrine tumour differentiation. Surgery was
thought to have been complete such that adjuvant radio-
therapy was not required. He remains free of recurrence at
79 months follow-up.
Discussion
Skin or soft tissue involvement in NET is rare and may rep-
resent either primary cutaneous disease or metastatic
spread from primary neuroendocrine disease elsewhere
usually in the lung or gastrointestinal tract [6]. There have
been seven previously published reports of primary NET
arising de novo in the skin but none where the tumour
originates in the limbs or soft tissues [7-12]. Previously
reported cases of primary skin NET were on the trunk or
scalp and were single nodules ranging from 1–4 cm in
diameter. The prognosis of these tumours appears favour-
able as recurrences are rare after prolonged follow-up
(Table 1).
The diagnosis of primary cutaneous or soft tissue NET
depends on exclusion of metastases from an occult
tumour elsewhere. Unlike in primary skin NET, skin
metastases from an occult primary are usually multiple
[9]. Since these tumours are slow growing indolent
tumours, metastasis tends to be a late manifestation of
advanced disease. The primary occult tumour will usually
have attained a diameter of at least 1 cm and not infre-
quently 2 cm particularly when arising in the appendix or
rectum [13,14]. Consequently, the primary tumour is usu-
ally large enough for detection by diagnostic imaging. Fur-
thermore, skin metastases from pulmonary or laryngeal
4 hour 123I mIBG scan of both feet in Case 2 Figure 3
4 hour 123I mIBG scan of both feet in Case 2. There is 
increased uptake of radionucleotide corresponding to the 
lesion on MRI.World Journal of Surgical Oncology 2007, 5:77 http://www.wjso.com/content/5/1/77
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NET are usually preceded by symptoms from the primary
tumour [15].
Identifying small primary tumours may be difficult with
conventional imaging techniques such as ultrasound, CT
and MRI [16]. Imaging with 123I mIBG shows a sensitivity
and specificity of approximately 60% in identifying neu-
roendocrine tumours [17]. Since NET usually express
somatostatin receptors, scanning with radiolabelled
somatostatin analogue (octreotide) is often helpful. Com-
pared with mIBG imaging, octreotide scanning is more
sensitive (72–87%) although less specific [18].
The presence of metastases is important prognostically as
survival is reduced from 70% at 5 years (without metas-
tases) to less than 50% (with metastases) [2].
Macroscopically, a NET usually appears as a yellow solid
tumour because of its high lipid content. Histologically,
they are composed of rows of cuboidal eosinophilic cells
arranged in trabecular, follicular or glandular patterns.
Definitive diagnosis requires specific histochemical and
immunohistochemical staining. Markers of neuroendo-
crine differentiation include neuron-specific enolase, syn-
aptophysin and chromogranin. Keratin staining
(including CAM 5.2) is generally concentrated at one edge
of the nucleus to give an appearance of "dot-like" keratin
positivity. Neurosecretory granules can be seen ultrastruc-
turally.
The differential diagnosis includes primary cutaneous
neoplasms arising from neurosecretory cells (Merkel cells)
in the skin. These tumours, known as Merkel cell carcino-
mas (MCC), are composed of uniform cells with scanty
neoplasm, round to ovoid nuclei with finely dispersed
chromatin, inconspicuous nucleoli and frequent mitotic
figures. Small membrane-bound dense granules are seen
in MCC at electron microscopy in contrast to NET where
granules are often large and irregular. Early reports of neu-
roendocrine differentiation in MCC utilised silver staining
reactions and demonstrated argyrophilia but negative
argentaffin reactions [19]. These have largely been super-
seded by specific stains for neuroendocrine markers such
as chromogranin which can be positive in either MCC or
NET. Immunohistochemical stains in MCC tumours
show variable positivity for cytokeratin and CK20 often in
a perinuclear arrangement in contrast to the more diffuse
staining seen in NET [20] and in the cases reported here.
More recently, distinctive cytogenetic abnormalities have
been described in MCC which may help differentiate
MCC from NET [21].
Clinically, MCC tumours are characterised by aggressive
behaviour with local recurrences, frequent metastases and
relatively poor response to conventional therapies
[21,22]. In case 1 the tumour clearly arose from muscle.
The tumour in case 2 could have originated in the skin
and invaded deeply as the histology showed it to be in the
subcutaneous tissue. However, it would have been MCC
stage II as the lymph nodes were involved and these
tumours have a median survival of only 5 months [23].
Similarly, the long recurrence-free survival in case 3 (also
with lymph node disease) makes this unlikely to have
been a MCC.
Table 1: Primary cutaneous neuroendocrine tumours
Reference Age M/F Clinical Ultrastructure Treatment Course
Van Dijk C et al, 1975 
[7]
72 yr Female Cystic lesion on forehead with 
flushing
Argophyllic granules Excision Flushing resolved. No 
recurrence × 1 yr
Brody HJ et al, 1979 [8] 75 yr Female Hyperpigmented nodule with 
periumbilical induration. Elevated 
5HIAA. Associated 
hyperparathyroidism
Strongly positive argentaffin 
reaction
Excision Not given in report
Collina et al, 1988 [26] 80 yr Male Nodule behind right ear × 12 m Argophyllic granules. 
Chromgranin positive Negative 
argentaffin reaction
Wide excision No recurrence 21 months 
later
Bart RS et al, 1990 [9] 40 yr Male Red-tan soft nodule on abdomen × 
4 years
Argophyllic large and varied 
granules. NSE, keratin +ve
Wide excision Alive and well 2 years 
later
Smith PA et al, 1995 
[10]
62 yr Female Firm blue-ish nodule on chest Argophyllic granules. Postive 
argentaffin reaction
Wide excision Alive at 4 years. Well 
apart from claudication
Courville P et al, 2000 
[11]
60 yr Male Erythematous nodule on chest Argophyllic granules. Positive 
argentaffin reaction. 
Chromogranin A, NSE
Excision Alive without recurrence 
4 years after excision
MacKenzie DN et al, 
2003 [12]
70 yr Female Hard node on scalp with metastasis 
to occipital lymph node
Synaptophysin, NSE, keratin, 
CEA +ve
Excision of 
lesion and 
occipital 
lymph node
4 years later further lymph 
node metastasis. 
Metastatic node 
recurrence 2 years laterWorld Journal of Surgical Oncology 2007, 5:77 http://www.wjso.com/content/5/1/77
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As with previous reports of cutaneous NET, primary surgi-
cal excision was the preferred treatment in our cases, com-
bined with nodal clearance in (case 3) or adjuvant
radiotherapy (case 1). Excision of a skin NET and lymph
node metastasis was successful in a previous case report
[12]. Disease control in our patients has been good at long
term follow-up.
In case 2, primary hypofractionated radiotherapy was
used as radical surgery was not possible. This approach
has been used for several other tumours e.g bladder, pros-
tate where patients are frail and cannot tolerate conven-
tionally fractionated radical doses [24]. Radiotherapy has
been used successfully to control unresectable NET in the
brain, spinal cord and bone [25]. Disease regression and
symptom palliation was achieved in the majority of
patients.
We believe these cases represent primary NET because no
evidence of tumour could be found elsewhere after fol-
low-up of 5 years. In only one patient were urinary 5 H-T
metabolites increased and this patient did not experience
features of the carcinoid syndrome presumably because
the quantity of peptides secreted was too low.
The soft tissue lesions in all our patients had advanced
slowly over a period of between 4 to 9 months and had
metastasized only to regional lymph nodes and not to dis-
tant organs.
In summary, these tumours appear to have a good prog-
nosis. Complete excision offers potentially curative treat-
ment. Staging is required to exclude lymph node or
distant metastases. Adjuvant radiotherapy may be helpful
when the tumour margin is narrow. Patients with recur-
rent disease or aggressive histopathological appearances
require radical radiotherapy doses. Although potentially
beneficial, uptake of mIBG and octreotide is probably
insufficient in the majority of cases to deliver tumouri-
cidal doses. For patients with unresectable disease or
where surgery would not be appropriate, radiotherapy
appears to be an effective therapeutic option.
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